Cargando…

New Translational Trends in Personalized Medicine: Autologous Peripheral Blood Stem Cells and Plasma for COVID-19 Patient

The COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), still remains a severe threat. At the time of writing this paper, the second infectious wave has caused more than 280,000 deaths all over the world. Italy was one of the first countries involved, with more...

Descripción completa

Detalles Bibliográficos
Autores principales: Balzanelli, Mario Giosuè, Distratis, Pietro, Lazzaro, Rita, D’Ettorre, Ernesto, Nico, Andrea, Inchingolo, Francesco, Dipalma, Gianna, Tomassone, Diego, Serlenga, Emilio Maria, Dalagni, Giancarlo, Ballini, Andrea, Nguyen, Kieu Cao Diem, Isacco, Ciro Gargiulo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778886/
https://www.ncbi.nlm.nih.gov/pubmed/35055400
http://dx.doi.org/10.3390/jpm12010085
_version_ 1784637438569742336
author Balzanelli, Mario Giosuè
Distratis, Pietro
Lazzaro, Rita
D’Ettorre, Ernesto
Nico, Andrea
Inchingolo, Francesco
Dipalma, Gianna
Tomassone, Diego
Serlenga, Emilio Maria
Dalagni, Giancarlo
Ballini, Andrea
Nguyen, Kieu Cao Diem
Isacco, Ciro Gargiulo
author_facet Balzanelli, Mario Giosuè
Distratis, Pietro
Lazzaro, Rita
D’Ettorre, Ernesto
Nico, Andrea
Inchingolo, Francesco
Dipalma, Gianna
Tomassone, Diego
Serlenga, Emilio Maria
Dalagni, Giancarlo
Ballini, Andrea
Nguyen, Kieu Cao Diem
Isacco, Ciro Gargiulo
author_sort Balzanelli, Mario Giosuè
collection PubMed
description The COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), still remains a severe threat. At the time of writing this paper, the second infectious wave has caused more than 280,000 deaths all over the world. Italy was one of the first countries involved, with more than 200,000 people reported as infected and 30,000 deaths. There are no specific treatments for COVID-19 and the vaccine still remains somehow inconclusive. The world health community is trying to define and share therapeutic protocols in early and advanced clinical stages. However, numbers remain critical with a serious disease rate of 14%, ending with sepsis, acute respiratory distress syndrome (ARDS), multiple organ failure (MOF) and vascular and thromboembolic findings. The mortality rate was estimated within 2–3%, and more than double that for individuals over 65 years old; almost one patient in three dies in the Intensive Care Unit (ICU). Efforts for effective solutions are underway with multiple lines of investigations, and health authorities have reported success treating infected patients with donated plasma from survivors of the illness, the proposed benefit being protective antibodies formed by the survivors. Plasma transfusion, blood and stem cells, either autologous or allograft transplantation, are not novel therapies, and in this short paper, we propose therapeutic autologous plasma and peripheral blood stem cells as a possible treatment for fulminant COVID-19 infection.
format Online
Article
Text
id pubmed-8778886
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87788862022-01-22 New Translational Trends in Personalized Medicine: Autologous Peripheral Blood Stem Cells and Plasma for COVID-19 Patient Balzanelli, Mario Giosuè Distratis, Pietro Lazzaro, Rita D’Ettorre, Ernesto Nico, Andrea Inchingolo, Francesco Dipalma, Gianna Tomassone, Diego Serlenga, Emilio Maria Dalagni, Giancarlo Ballini, Andrea Nguyen, Kieu Cao Diem Isacco, Ciro Gargiulo J Pers Med Case Report The COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), still remains a severe threat. At the time of writing this paper, the second infectious wave has caused more than 280,000 deaths all over the world. Italy was one of the first countries involved, with more than 200,000 people reported as infected and 30,000 deaths. There are no specific treatments for COVID-19 and the vaccine still remains somehow inconclusive. The world health community is trying to define and share therapeutic protocols in early and advanced clinical stages. However, numbers remain critical with a serious disease rate of 14%, ending with sepsis, acute respiratory distress syndrome (ARDS), multiple organ failure (MOF) and vascular and thromboembolic findings. The mortality rate was estimated within 2–3%, and more than double that for individuals over 65 years old; almost one patient in three dies in the Intensive Care Unit (ICU). Efforts for effective solutions are underway with multiple lines of investigations, and health authorities have reported success treating infected patients with donated plasma from survivors of the illness, the proposed benefit being protective antibodies formed by the survivors. Plasma transfusion, blood and stem cells, either autologous or allograft transplantation, are not novel therapies, and in this short paper, we propose therapeutic autologous plasma and peripheral blood stem cells as a possible treatment for fulminant COVID-19 infection. MDPI 2022-01-10 /pmc/articles/PMC8778886/ /pubmed/35055400 http://dx.doi.org/10.3390/jpm12010085 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Balzanelli, Mario Giosuè
Distratis, Pietro
Lazzaro, Rita
D’Ettorre, Ernesto
Nico, Andrea
Inchingolo, Francesco
Dipalma, Gianna
Tomassone, Diego
Serlenga, Emilio Maria
Dalagni, Giancarlo
Ballini, Andrea
Nguyen, Kieu Cao Diem
Isacco, Ciro Gargiulo
New Translational Trends in Personalized Medicine: Autologous Peripheral Blood Stem Cells and Plasma for COVID-19 Patient
title New Translational Trends in Personalized Medicine: Autologous Peripheral Blood Stem Cells and Plasma for COVID-19 Patient
title_full New Translational Trends in Personalized Medicine: Autologous Peripheral Blood Stem Cells and Plasma for COVID-19 Patient
title_fullStr New Translational Trends in Personalized Medicine: Autologous Peripheral Blood Stem Cells and Plasma for COVID-19 Patient
title_full_unstemmed New Translational Trends in Personalized Medicine: Autologous Peripheral Blood Stem Cells and Plasma for COVID-19 Patient
title_short New Translational Trends in Personalized Medicine: Autologous Peripheral Blood Stem Cells and Plasma for COVID-19 Patient
title_sort new translational trends in personalized medicine: autologous peripheral blood stem cells and plasma for covid-19 patient
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778886/
https://www.ncbi.nlm.nih.gov/pubmed/35055400
http://dx.doi.org/10.3390/jpm12010085
work_keys_str_mv AT balzanellimariogiosue newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient
AT distratispietro newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient
AT lazzarorita newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient
AT dettorreernesto newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient
AT nicoandrea newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient
AT inchingolofrancesco newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient
AT dipalmagianna newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient
AT tomassonediego newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient
AT serlengaemiliomaria newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient
AT dalagnigiancarlo newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient
AT balliniandrea newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient
AT nguyenkieucaodiem newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient
AT isaccocirogargiulo newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient